NeoStem,
Inc. NBS, its subsidiary, Progenitor Cell Therapy LLC ("PCT"), and
ImmunoCellular Therapeutics, Ltd. IMUC ("IMUC"), a clinical-stage
biotechnology company that is developing immune-based therapies for the
treatment of brain and other cancers, announced today the execution of a
Services Agreement under which PCT will provide cGMP ("current good
manufacturing practices") manufacturing services to support research and
development of IMUC's ICT-121 cell therapy product candidate, a dendritic cell
vaccine targeting CD133 cells. PCT currently provides manufacturing services
for IMUC's lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma, for its Phase
II clinical trial.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in